Itonis Pharmaceuticals, Led by Dr. Charles Hensley, the Inventor of Zicam(R) Cold Remedy, Received FDA Labeler Status
July 31 2013 - 9:00AM
Marketwired
Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the
inventor of the Zicam® cold remedy, are pleased to announce that
the Company has received its labeler's code from the federal Food
and Drug Administration (FDA).
The labeler's code is the company component of the National Drug
Code (NDC) that identifies Itonis as the pharmaceutical company
responsible for all of its homeopathic products.
Dr. Hensley commented, "We expect to receive the product
component of the NDC for Emesyl from the FDA within the next few
weeks."
Emesyl is Itonis' nausea relief product.
About Itonis Pharmaceuticals Itonis
Pharmaceuticals, a new division of Itonis, Inc., is headed by
Charles Hensley, Ph.D. This division's mission is to create and
market over-the-counter and prescription homeopathic products that
better people's lives. Dr. Hensley is a pioneer in the development
and marketing of safe and effective therapeutic nutraceutical and
homeopathic preparations. He was a founder of the company that
launched the Zicam® Cold Remedy, making the product a household
name and forever changing the marketing and product placement
paradigm for homeopathic drugs in the United States. Dr. Hensley
and his team plan to use the same methodologies to revolutionize
the treatment of several other common ailments and other chronic
diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5,
2005 under the name of Kenshou, Inc., which later changed to
Itonis, Inc. on December 2, 2005. Please visit
www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Michael Biddick Email Contact (949) 529-1588
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Apr 2023 to Apr 2024